Table 2.

Overview of study protocols and treatment regimens

Author	Diuretic dosage before	Therapy	Treatment regiment	1 visit	>1 visit	Visit per patient	Length of follow‐up
Ryder	NA	Furosemide i.v.	40‐80 mg bolus	72%	28%	NA	NA
Freimark	NA	Furosemide i.v. ± metolazone ± inotropic medication	NA	NA	NA	NA	12 months
Hebert	NA	Furosemide i.v. ± metolazone	40 mg bolus + infusion 160 mg	NA	NA	1‐14	17 months
Lazkani	NA	Furosemide/bumetanide i.v. + metolazone	Dosage not mentioned	86%	14%	1‐2	30 days
Banerjee	NA	Furosemide i.v.	80‐100 mg bolus	83%	17%	1‐2	30 days
Makadia	Mean oral 160 mg furosemide	Furosemide ± metolazone	Continuous infusion furosemide (mean 100 mg)	NA	NA	1‐22	NA
Buckley	Mean oral 240 mg (80‐800 mg) furosemide	Furosemide i.v.	Bolus furosemide and continuous infusion	55%	45%	NA	60 days
Al‐Ani	Mean oral 160 mg furosemide or equivalent	Furosemide i.v.	Bolus 80 mg	NA	NA	30 visits for 19 patients	NA
Buckley	Mean 396 mg ± 375 furosemide or equivalent	Furosemide i.v.	Bolus furosemide and continuous infusion	NA	NA	483 visits for 283 patients	NA
Zatarain	NA	Furosemide s.c.	Furosmide continuously s.c., mean 146 mg/day	NA	NA	41 episodes for 24 patients, mean 9 ± 4 days	NA
Gilotra	Mean 246 mg ± 167 mg furosemide	Furosemide s.c. or i.v.	Randomization between fixed single bolus of furosemide s.c. 80 mg and intravenous bolus of 80‐160 mg (mean 123 ± 47 mg)	NA	NA	NA	30 days

i.v., intravenous; NA, not available; s.c., subcutaneously